The combination of drugs shows a promise for the treatment of aggressive T-cell lymphomas

Recommitant/durable peripheral and T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard treatment. Patients with these lymphomas may require stem cell transplants, but the disease should be brought under control before patients may be undergoing this treatment. A new study by researchers from the Petal consortium at Mass General Brigham found that the combination of Duvelisib and Romidepsin is effective, tolerated and safe for patients with R/R PTCL and CTCL. Their findings indicate that this combination of drugs offers a new strategy to help these patients control the disease in order to be eligible for stem cell transplants. The results are published in Progresses blood.

This real world study is based on previous clinical trials by providing a more comprehensive view of the use of the combination of medicines in clinical practice, including variations in the clinical environment, prescription standards and adverse events management in a different population of higher risk. Despite the dose modifications and holidays, high response rates were observed to patients. ”

Josie Ford, BS, First Author, Clinical Research Coordinator at Massachusetts General Hospital

Clinicians have given treatment in 38 patients, monitoring the efficacy of treatment, how long the patient lived and side effects. The results of the study showed that the combination of drugs helped to shrink or eliminate cancer to 61% of patients, while 47% did not have cancer detectable. Eleven patients continued to receive stem cell transplants. In addition, in patients with the nodular T-lubricant of the lymphoma auxiliary cell, 82% of patients responded well. The combination of drugs had manageable side effects, but a patient died of treatment -related complications.

“These findings support the efficiency, safety and tolerance of Duvelisib and Romidepsin and we hope that the study will facilitate the improvement of access to treatment through insurance coverage and regulatory approvals,” said senior author Salvia Jain, MD, Founding Member Mgh. “The future direction will be in the determination of response or resistance indicators, ideally through non -invasive monitoring so that the treatment can be personalized.”